Our data suggest that CELF1 is a viable therapeutic target, as repression of CELF activity restores normal alternative splicing of CELF-responsive dysregulated transcripts in cell culture and transgenic mouse models of DM1 skeletal muscle. Here, CEBPD is linked to myotonic dystrophy type 1.